Masterclass: Evidence on the Use of SGLT2is in HF Across the EF Spectrum

Подробнее о видео

Watch on Radcliffe Cardiology:

Masterclass host, Dr Harriette Van Spall (McMaster University, CA) invites Dr Scott D Solomon (Brigham & Women's Hospital & Harvard Medical School, US) and Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the latest evidence supporting the use of SGLT2 inhibitors in heart failure across the ejection fraction spectrum.

Dr Solomon provides a brief overview on the existing data including DAPA-HF, EMPEROR-Reduced and Preserved. Dr Kosiborod shares the insights from the DEFINE-HF & PRESERVED-HF Pooled Analysis. Dr Van Spall asks Dr Solomon about DELIVER and the knowledge gap it fills.

Recorded remotely from Hamilton, Boston and Kansas City, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.